Arrowhead Pharmaceuticals, Inc. (ARWR)
78.31
-0.83
(-1.05%)
USD |
NASDAQ |
May 07, 09:44
Arrowhead Pharmaceuticals Cash from Investing (Quarterly) : -23.74M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Sarepta Therapeutics, Inc. | 96.21M |
| Johnson & Johnson | -1.04B |
| Biogen, Inc. | -209.50M |
| Merck & Co., Inc. | -10.21B |
| Vertex Pharmaceuticals, Inc. | -431.90M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 13.48M |
| Cash from Financing (Quarterly) | -14.75M |
| Free Cash Flow | 327.01M |
| Free Cash Flow Per Share (Quarterly) | 0.0805 |
| Free Cash Flow to Equity (Quarterly) | 57.25M |
| Free Cash Flow to Firm (Quarterly) | 33.81M |
| Free Cash Flow Yield | 3.04% |